The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Amneal Pharmaceuticals Inc (NASDAQ: AMRX) closed at $11.87 in the last session, down -2.55% from day before closing price of $12.18. In other words, the price has decreased by -$2.55 from its previous closing price. On the day, 1.79 million shares were traded. AMRX stock price reached its highest trading level at $12.25 during the session, while it also had its lowest trading level at $11.855.
Ratios:
We take a closer look at AMRX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.81 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.95. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 2.13.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on June 06, 2025, initiated with a Buy rating and assigned the stock a target price of $12.
On February 24, 2025, JP Morgan Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $9 to $12.
JP Morgan Upgraded its Underweight to Neutral on September 06, 2024, while the target price for the stock was maintained at $9.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 17 ’25 when Nark Ted C sold 50,000 shares for $11.72 per share. The transaction valued at 586,000 led to the insider holds 291,029 shares of the business.
Nark Ted C bought 50,000 shares of AMRX for $591,250 on Nov 17 ’25. On Nov 12 ’25, another insider, Shah Nikita, who serves as the Executive Vice President of the company, sold 131,856 shares for $11.92 each. As a result, the insider received 1,571,724 and left with 146,403 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMRX now has a Market Capitalization of 3731487744 and an Enterprise Value of 6378472448. As of this moment, Amneal’s Price-to-Earnings (P/E) ratio for their current fiscal year is 835.92, and their Forward P/E ratio for the next fiscal year is 12.81. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 33.41. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.27. Its current Enterprise Value per Revenue stands at 2.173 whereas that against EBITDA is 10.225.
Stock Price History:
The Beta on a monthly basis for AMRX is 1.35, which has changed by 0.49447858 over the last 52 weeks, in comparison to a change of 0.13844287 over the same period for the S&P500. Over the past 52 weeks, AMRX has reached a high of $12.68, while it has fallen to a 52-week low of $6.68. The 50-Day Moving Average of the stock is 7.62%, while the 200-Day Moving Average is calculated to be 32.02%.
Shares Statistics:
According to the various share statistics, AMRX traded on average about 1.74M shares per day over the past 3-months and 1918590 shares per day over the past 10 days. A total of 314.31M shares are outstanding, with a floating share count of 156.64M. Insiders hold about 50.17% of the company’s shares, while institutions hold 44.16% stake in the company. Shares short for AMRX as of 1763078400 were 6575260 with a Short Ratio of 3.77, compared to 1760486400 on 5754980. Therefore, it implies a Short% of Shares Outstanding of 6575260 and a Short% of Float of 3.25.
Earnings Estimates
Currently, 4.0 analysts are dedicated to thoroughly evaluating and rating the performance of Amneal Pharmaceuticals Inc (AMRX) in the stock market.The consensus estimate for the next quarter is $0.19, with high estimates of $0.21 and low estimates of $0.18.
Analysts are recommending an EPS of between $0.82 and $0.78 for the fiscal current year, implying an average EPS of $0.8. EPS for the following year is $0.94, with 4.0 analysts recommending between $1.03 and $0.89.
Revenue Estimates
According to 4 analysts,. The current quarter’s revenue is expected to be $808.14M. It ranges from a high estimate of $822.7M to a low estimate of $790.11M. As of. The current estimate, Amneal Pharmaceuticals Inc’s year-ago sales were $730.52MFor the next quarter, 4 analysts are estimating revenue of $741.79M. There is a high estimate of $748.71M for the next quarter, whereas the lowest estimate is $728.7M.
A total of 4 analysts have provided revenue estimates for AMRX’s current fiscal year. The highest revenue estimate was $3.03B, while the lowest revenue estimate was $2.99B, resulting in an average revenue estimate of $3.01B. In the same quarter a year ago, actual revenue was $2.79BBased on 4 analysts’ estimates, the company’s revenue will be $3.21B in the next fiscal year. The high estimate is $3.23B and the low estimate is $3.18B.
